Biocytogen's antibody discovery team has generated a library of antibodies targeting approximately 200 tumor-associated antigens (TAAs) using three RenMice® platforms - RenMabTM, RenLite®, and RenNano®. RenMice generate fully human antibodies, facilitating the discovery and development of therapeutic monoclonal antibodies, bispecific/multispecific antibodies, and single-domain antibodies. Engineered with a specific target gene knocked out, RenMice are designed to trigger potent immune responses against homologous proteins and produce antibodies that bind more broadly to epitopes, increasing the chance of discovering antibodies with therapeutic potential. Many of the TAA-targeting antibodies discovered from RenMice have been screened for internalization activity to ensure suitability for ADC development. This ready-to-use resource expedites the development of antibody-drug conjugates (ADCs) across various modalities.